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Introduction
Ischemic heart disease is the leading cause of death worldwide, 
causing about 8.8 million deaths in 2015 and accounting for approx-
imately 15.5% of all deaths that year (1). Prompt revascularization 
by percutaneous coronary intervention or bypass surgery markedly 
reduces acute mortality from myocardial infarction (MI); howev-
er, increased morbidity due to ischemic heart failure has become a 
global burden (2), highlighting the need for additional therapeutic 
modalities to alleviate postischemic cardiovascular remodeling.
Evidence indicates that endothelial dysfunction is a key com-
ponent of the pathophysiology of heart failure (3, 4). VEGF-A, 
referred to herein as VEGF, is highly expressed in myocardial 
cells. While VEGF helps preserve the cardiac capillary bed under 
homeostatic conditions, it acts as a stimulating factor for angio-
genesis, vascular leakage, and inflammation under ischemic con-
ditions (5–11). VEGF is downregulated during the transition from 
compensated hypertrophy to decompensated heart failure, reduc-
ing its capacity to preserve the cardiac capillary bed or to gener-
ate new vessels in response to cardiac hypertrophy (3). Although 
a multitude of animal studies have shown that VEGF induces 
angiogenesis in the ischemic myocardium and that it mitigates 
adverse remodeling, to date, clinical trials of VEGF have not yet 
demonstrated any clinical benefits (5). This discrepancy is likely 
due to the negative effect of VEGF on the ischemic heart. Indeed, 
VEGF exacerbates tissue damage after MI (6) and ischemic stroke 
(7) by inducing the disintegration of endothelial cells (ECs), there-
by aggravating vascular leakage, inflammation, and hypoxia (8). 
Inhibiting VEGF-induced vascular permeability can reduce tissue 
edema and improve outcome in MI (8) and stroke (7). However, 
due to the angiogenic and cytoprotective effects of VEGF (9), 
VEGF inhibition after MI confronts a major hurdle that can exac-
erbate ischemia and therefore tissue damage.
Angiopoietins, the other family of major angiogenic growth 
factors, regulate vascular maturation and stability by binding to 
the endothelial cell–specific (EC-specific) Tie2 receptor and to 
subtypes of integrins (10, 11). Angiopoietin-1 (Angpt1) is an ago-
nistic ligand of Tie2 that maintains the quiescence and integrity of 
ECs (12). In contrast, Angpt2 is a partial Tie2 antagonist or agonist 
that can modulate Angpt1/Tie2 signaling in context-dependent 
(10) and organ-specific manners (13–16). Hypoxia and inflam-
mation induce Angpt2 expression on ECs (17), which destabiliz-
es endothelial integrity (18). Although the deleterious effects of 
Angpt2 in augmenting vascular permeability and inflammation 
have been intensely investigated in sepsis and tumor angiogen-
esis (14), the precise role of Angpt2 in ischemic heart disease 
remains poorly elucidated. Emerging reports show that Angpt2 
is associated with a greater risk of all-cause and cardiovascular 
mortality in the general population (19), with the deterioration 
of cardiac function in heart failure patients (20), and with high-
er mortality in MI and cardiogenic shock patients (21, 22). Given 
these meaningful findings, we investigated the role of Angpt2 in 
cardiac ischemia using mouse models. Our findings demonstrate 
that Angpt2 substantially exacerbates postischemic cardiovascu-
lar remodeling, including pericyte detachment, adhesion mole-
Emerging evidence indicates that angiopoietin-2 (Angpt2), a well-recognized vascular destabilizing factor, is a biomarker 
of poor outcome in ischemic heart disease. However, its precise role in postischemic cardiovascular remodeling is poorly 
understood. Here, we show that Angpt2 plays multifaceted roles in the exacerbation of cardiac hypoxia and inflammation 
after myocardial ischemia. Angpt2 was highly expressed in endothelial cells at the infarct border zone after myocardial 
infarction (MI) or ischemia/reperfusion injury in mice. In the acute phase of MI, endothelial-derived Angpt2 antagonized 
Angpt1/Tie2 signaling, which was greatly involved in pericyte detachment, vascular leakage, increased adhesion molecular 
expression, degradation of the glycocalyx and extracellular matrix, and enhanced neutrophil infiltration and hypoxia in the 
infarct border area. In the chronic remodeling phase after MI, endothelial- and macrophage-derived Angpt2 continuously 
promoted abnormal vascular remodeling and proinflammatory macrophage polarization through integrin α5β1 signaling, 
worsening cardiac hypoxia and inflammation. Accordingly, inhibition of Angpt2 either by gene deletion or using an anti-
Angpt2 blocking antibody substantially alleviated these pathological findings and ameliorated postischemic cardiovascular 
remodeling. Blockade of Angpt2 thus has potential as a therapeutic option for ischemic heart failure.
Angiopoietin-2 exacerbates cardiac hypoxia and 
inflammation after myocardial infarction
Seung-Jun Lee,1 Choong-kun Lee,1,2 Seok Kang,1,2 Intae Park,1,2 Yoo Hyung Kim,1,2 Seo Ki Kim,1,2 Seon Pyo Hong,1,2  
Hosung Bae,1,2 Yulong He,3 Yoshiaki Kubota,4 and Gou Young Koh1,2
1Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea. 2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST),  
Daejeon, South Korea. 3Cyrus Tang Hematology Center, Soochow University, Suzhou, China. 4The Laboratory of Vascular Biology, School of Medicine, Keio University, Tokyo, Japan.
Conflict of interest: The authors have declared that no conflict of interest exists.
License: Copyright 2018, American Society for Clinical Investigation.
Submitted: January 5, 2018; Accepted: August 21, 2018.
Reference information: J Clin Invest. 2018;128(11):5018–5033. 
https://doi.org/10.1172/JCI99659.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 0 1 9jci.org   Volume 128   Number 11   November 2018
FOXO1 is an upstream regulator of Angpt2 expression in ECs of 
the border zone. We next investigated the spatiotemporal expres-
sion of forkhead box protein O1 (FOXO1), an upstream transcrip-
tional regulator of Angpt2 expression in the ECs after MI (25). In 
the sham-operated control mouse heart, neither ECs nor cardio-
myocytes (CMs) expressed FOXO1 (Figure 2A). In contrast, there 
was a striking increase in FOXO1 expression, which is known to 
protect CMs against ischemic insult through regulation of antioxi-
dant genes, in CMs in the infarct border area of MI mice (26). This 
increase was distinct 1 day after MI and then rapidly decreased (Fig-
ure 2, A and B). Of particular note, FOXO1 expression was robustly 
increased and showed nuclear or nucleocytoplasmic localization 
in ECs at the border zone 2 days after MI, which correlates with 
the Angpt2 expression profile (Figure 2, A and B). Immunoblot 
analysis demonstrated a consistent finding of increased FOXO1 
expression after MI (Figure 2, C and D). Indeed, concurrent 
Angpt2 expression and FOXO1 nuclear localization were observed 
in the ECs (Figure 2E). To investigate whether FOXO1 directly reg-
ulated Angpt2 expression in ECs, we generated Foxo1iΔEC mice by 
crossing Foxo1fl/fl mice (27) with VE-cadherin–Cre-ERT2 mice (28) 
(Figure 2F), which depleted endothelial FOXO1 by approximately 
85% (Supplemental Figure 2, A–C). EC-specific deletion of Foxo1 
using Foxo1iΔEC mice markedly reduced Angpt2 expression in ECs 
(Figure 2, G and H). Taken together, these findings indicate that 
FOXO1 is a major transcriptional upstream regulator of Angpt2 
expression in the ECs of murine ischemic hearts.
Angpt2 induces pericyte detachment from ECs of infarct border 
zone through antagonizing Angpt1/Tie2 signaling. Angpt2 is charac-
terized by its context-dependent mode of action, which functions 
cule expression, glycocalyx and extracellular matrix (ECM) deg-
radation, proinflammatory macrophage polarization, and adverse 
vascular remodeling. These findings identify Angpt2 as a potential 
promising therapeutic target in ischemic heart disease, and anti-
body-mediated inhibition of Angpt2 ameliorates cardiac hypoxia 
and inflammation after MI.
Results
Angpt2 is highly expressed in ECs at the infarct border zone after MI. 
To determine the expression profile of Angpt2 in mouse heart 
after MI, we utilized a specific anti-Angpt2 antibody (23). High 
Angpt2 expression was observed in the infarct border zone 3 
days after MI, while no Angpt2 expression was observed in sham- 
operated hearts (Figure 1A). A high-magnification view showed 
that Angpt2 expression was confined mainly to ECs at the border 
zone (Figure 1B). Sequential observations of ECs in the expand-
ing infarct border revealed that Angpt2 expression began on day 
2, peaked on day 3, and was maintained at the peak level until 
day 7 after MI (Figure 1, C and D). In vivo reporter gene analy-
sis using Angpt2-EGFP mice confirmed that the increased Angpt2 
expression was confined to the ECs (Figure 1, E and F). To fur-
ther determine the identity of ECs expressing Angpt2, we uti-
lized endothelial-lineage tracing mouse (VE-cadherin–Cre-ERT2/
Rosa-tdTomato, Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI99659DS1) and a marker for circuiting ECs (CD117) (24). 
Lineage-tracing analysis revealed that Angpt2 is almost exclusive-
ly expressed in ECs residing in the heart, rather than circulating 
ECs expressing CD117 (Supplemental Figure 1, B and C).
Figure 1. Angpt2 is highly 
expressed in ECs of the border 
zone after MI. Adult WT mice were 
subject to MI or sham procedure 
(Sh), hearts were harvested at indi-
cated time points, and indicated 
molecules in heart sections were 
detected by immunostaining. (A 
and B) Images for Angpt2 in ECs 
at the infarct border. Scale bars: 
500 μm (A); 20 μm (B). (C and D) 
Temporal changes of Angpt2 in 
border zone ECs at indicated day 
after MI. n = 6, each time point. 
Each box region is magnified below. 
Scale bars: 100 μm. *P < 0.05 
versus sham, Mann-Whitney U test. 
(E and F) Images and comparisons 
of Angpt2 expression in ECs at 
the infarct border of Angpt2-EGFP 
mice. Box region is magnified at 
right. n = 5, each group. Scale bars: 
100 μm. *P < 0.05 versus sham, 
Mann-Whitney U test. Error bars 
represent mean ± SD.
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glomerular function (Supplemental Figure 3C), which showed no 
significant differences between the Angpt2iΔEC and WT mice. Heart 
ECs of sham-operated mice demonstrated robust Tie2 phosphor-
ylation, which was markedly reduced after MI (Figure 3, D and E). 
Of note, the reduction in Tie2 phosphorylation in ECs after MI was 
further exacerbated in Angpt1iΔ/Δ mice, but was markedly mitigated 
in Angpt2iΔEC mice (Figure 3, D and E). These findings imply that 
Angpt2 acts as a Tie2 antagonist in the ischemic heart. Given that 
Angpt2-induced Tie2 inactivation causes pericytes to detach from 
ECs in inflammatory conditions (14, 25, 30), we examined the ratio 
of pericyte coverage onto ECs of the border zone. As shown in Fig-
ure 3, F and G, the ECs with high Angpt2 expression had 55% less 
pericyte coverage than the ECs with no or low Angpt2 expression. 
Consistently, pericyte detachment from ECs of the border zone at 
3 days after MI was reduced by 59% in Angpt2iΔEC mice compared 
with WT mice (Figure 3, H and I), suggesting the disintegrative role 
of Angpt2 in the microvasculature of the ischemic heart.
as a Tie2 agonist in the absence of Angpt1, but as an antagonist in 
the presence of Angpt1 (14). Therefore, we investigated the expres-
sion of Angpt1 in the heart using Angpt1-GFP reporter mice (29). 
In sham-operated control mice, Angpt1 expression marked by 
GFP fluorescence was found to be heterogeneous, but distinctly 
expressed throughout the myocardium, but the expression was not 
apparently changed at 3 days after MI in surviving myocardium 
(Figure 3, A and B). To evaluate the impact of Angpt1 and Angpt2 
on Tie2 phosphorylation in ECs at the border zone, we generated 
Angpt1iΔ/Δ mice by crossing Angpt1fl/fl mice (29) with UBC-Cre-ERT2 
mice and Angpt2iΔEC mice by crossing Angpt2fl/fl mice (27) with 
VE-cadherin–Cre-ERT2 mice (28) (Figure 3C). Littermates that were 
Cre-ERT2 positive but flox/flox negative were defined as WT mice. 
Given the organ-specific role of Anpgt2 in the development and 
maturation of the vasculature, such as the vasculature of the kidney 
and Schlemm’s canal of the eye (14, 15, 30–32), we investigated the 
systemic vascular function (Supplemental Figure 3, A and B) and 
Figure 2. Marked increase of FOXO1 governs 
Angpt2 expression in ECs of the infarct 
border after MI. Adult WT or Foxo1iΔEC mice 
were subject to MI or sham procedure, hearts 
were harvested at indicated time points, and 
indicated molecules in heart sections were 
detected by immunostaining. CM borders are 
highlighted by wheat germ agglutinin (WGA) 
staining. (A) Temporal changes of expression 
and distribution of FOXO1 after MI. Note 
rapidly increased FOXO1 in CMs (blue aster-
isks) at day 1 after MI and prominent nuclear 
(white arrows) or nucleocytoplasmic (yellow 
arrowheads) localization of FOXO1 in ECs at 
day 2 after MI. Each box region is magnified in 
left corner. Scale bars: 50 μm. (B) Compari-
sons of relative FOXO1 expression in CMs and 
ECs after MI. n = 4–5, each time point. *P < 
0.05 versus sham, Mann-Whitney U test. (C 
and D) Immunoblot and densitometric analy-
ses of indicated proteins at the infarct border 
after MI. Note increased expression of FOXO1 
after MI. n = 3, each group. *P < 0.05 versus 
sham, Mann-Whitney U test. (E) Images 
representing nuclear localization of FOXO1 in 
Angpt2+ border zone ECs (white arrowheads) 
at 3 days after MI. Scale bar: 20 μm. (F) Dia-
gram depicting generation of Foxo1iΔEC mice 
and experiment schedule. (G and H) Images 
and comparisons of Angpt2 expression in the 
ECs of WT and Foxo1iΔEC (F1ΔE) mice. n = 5,  
each group. Scale bars: 50 μm. *P < 0.05 
versus WT, Mann-Whitney U test. Error bars 
represent mean ± SD.
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Tie1 is an endothelial orphan 
receptor and a homolog of Tie2 
that positively modulates Tie2 
signaling (33, 34). Given that Tie1 
expression is reduced during 
inflammation and that this 
reduced Tie1 allows enhanced 
antagonistic action of Angpt2 
against Tie2 (25, 34, 35), we were 
curious about the expression level 
of the Tie1 protein in ECs of the 
border zone. Immunohistological 
analysis revealed that Tie1 was 
highly present in cardiac ECs of 
sham-operated control mice, but 
marked and gradual decline of 
Tie1 was detected at days 1 and 3 
after MI (Figure 3, J and K). This 
finding implies that the antagonis-
tic action of Angpt2 to Tie2 could 
be enforced in the ECs at the bor-
der zone. To further confirm the 
observed changes in immunoflu-
orescence staining, expression of 
each protein after MI was inves-
tigated by immunoblotting or the 
immunoprecipitation method, 
which showed consistent results 
with immunostaining (Supple-
mental Figure 4, A–D).
EC-derived Angpt2 exacerbates 
vascular leakage, cardiac hypox-
ia, and infarction. We and others 
recently reported that Angpt2 
mediates vascular leakage in 
severe inflammatory conditions, 
leading to impairment of micro-
vascular perfusion and organ 
damage (23, 36). To investigate 
whether EC-derived Angpt2 and 
its Tie2-antagonizing action on 
ECs at the border zone contrib-
ute to vascular disintegration and 
infarct progression, Angpt2iΔEC 
(gene deletion efficiency, ~93%; 
Supplemental Figure 5 and Sup-
plemental Table 1) and WT mice 
were subjected to the MI pro-
cedure or to a sham procedure, 
and vascular leakage, perfusion, 
hypoxic molecule expression, 
and the infarct size were com-
pared 3 days after surgery. Vas-
cular leakage of low–molecular 
weight (40 kDa) dextran from 
the border zone microvasculature 
was markedly reduced, by 71%, 
Figure 3. Angpt2 destabilizes endothelial integrity of ischemic heart by antagonizing Angpt1/Tie2 signal-
ing. Adult WT, Angpt1iΔ/Δ (A1ΔU), or Angpt2iΔEC (A2ΔE) mice were subjected to MI or sham procedure, and 
hearts were harvested at 3 days after MI. (A and B) Images and comparisons of Angpt1 expression in heart 
of Angpt1-GFP mice at 3 days after sham or MI procedure. Each region marked by a box demonstrating the 
expression of Angpt1 in myocardium is magnified in the right corner. Scale bars: 500 μm. n = 4–5. (C) Diagram 
depicting generation of Angpt1iΔ/Δ or Angpt2iΔEC mice and experiment schedule. (D and E) Immunofluorescence 
images and quantification show the decrease in pTie2 in border zone ECs after MI; pTie2 level was lower 
in Angpt1iΔ/Δ mice, but higher in Angpt2iΔEC mice compared with WT. Scale bars: 100 μm. n = 5–6, each time 
point. *P < 0.01, Kruskal-Wallis test followed by Mann-Whitney U test for post hoc pairwise comparisons. 
(F and G) Images and comparisons of NG2+ pericyte (PC) coverage on ECs at the border zone. Direction of 
arrow indicates the border zone closer to infarct area. Dashed lines distinguish PChi/Angpt2lo region from 
PClo/Angpt2hi region at the infarct border. PC coverage was compared between the ECs within high Angpt2 
expression zone (A2hi) and low Angpt2 expression zone (A2lo). n = 4, each group. Scale bars: 100 μm. *P < 
0.05 versus A2lo zone, Mann-Whitney U test. (H and I) Images and comparisons of NG2+ PC coverage onto 
ECs at the border zone. n = 5–6, each group. Scale bars: 50 μm. *P < 0.025, Kruskal-Wallis test followed by 
Mann-Whitney U test for post hoc pairwise comparisons (WT versus sham and WT versus Angpt2iΔEC). (J and 
K) Temporal changes of relative expression of Tie1 in the ECs of infarct border. n = 5–6, each time point. Scale 
bars: 50 μm. *P < 0.05 versus sham, Mann-Whitney U test. Error bars represent mean ± SD.
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cantly mitigated in Angpt2iΔEC mice compared with WT mice. On 
the other hand, leakage and hypoxia were further exacerbated in 
Angpt1iΔ/Δ mice (Figure 4, C and D) and Tie2iΔEC mice (Supplemen-
tal Figure 6, B and C) compared with WT mice. Indeed, the sizes 
of infarcts in Angpt2iΔEC mice were significantly smaller (42 %, P = 
0.008) than those in WT mice (Figure 4, E and F). Together, these 
results indicate that, after MI, EC-derived Angpt2 could antag-
onize endothelial Tie2 phosphorylation and exacerbate cardiac 
hypoxia and infarct progression by aggravating vascular leakage 
and microvascular hypoperfusion.
EC-derived Angpt2 aggravates vascular inflammation and myo-
cardial remodeling after MI. An excessive and uncontrolled inflam-
matory response after MI exacerbates the pathological remodel-
ing of the infarcted cardiac tissue (39). Given the augmenting role 
in Angpt2iΔEC mice, and lectin perfusion was improved by 69% in 
Angpt2iΔEC mice compared with WT mice (Figure 4, A and B). Con-
sequently, cardiac hypoxia as measured by Hypoxyprobe-1 stain-
ing was improved by 63% in Angpt2iΔEC mice compared with WT 
mice (Figure 4, A and B). To gain further insight into the contrib-
uting role of the Angpt-Tie2 system on vascular integrity after MI, 
Angpt1iΔ/Δ and Tie2iΔEC mice were also subjected to MI or sham pro-
cedure, and the impact of the deletion of either gene on vascular 
leakage and hypoxia was investigated. We generated Tie2iΔEC mice 
by crossing Tie2fl/fl mice (37) with VE-cadherin–Cre-ERT2 mice 
(28) (Supplemental Figure 6A) and depleted Tie2 in a tamoxifen- 
inducible manner (deletion efficiency, ~94%; Supplemental Fig-
ure 5 and Supplemental Table 1). Leakage of RBCs and expres-
sion of GLUT-1, another marker for hypoxia (38), were signifi-
Figure 4. EC-specific depletion of 
Angpt2 mitigates vascular leakage  
and improves microvascular per-
fusion and tissue oxygenation in 
ischemic heart. Adult WT, Angpt1iΔ/Δ, 
or Angpt2iΔEC mice were subject to MI 
or sham procedure, and hearts were 
harvested at 3 days after MI. (A and 
B) Images and comparisons of dextran 
leakage, FITC-lectin perfusion, and 
Hypoxyprobe+ hypoxic area. n = 5–6, 
each group. Scale bars: 50 μm. *P < 
0.025, Kruskal-Wallis test followed 
by Mann-Whitney U test for post 
hoc pairwise comparisons. (C and D) 
Images and comparisons of TER119+ 
RBC leakage, and GLUT1+ hypoxic area. 
n = 5–6, each group. Scale bars: 200 
μm. *P < 0.01, Kruskal-Wallis test 
followed by Mann-Whitney U test 
for post hoc pairwise comparisons. 
(E and F) Representative images of 
TTC-stained cross-sections at middle 
and apical portions of hearts. White 
area demarcated by dashed lines 
corresponds to infarcted region. Each 
infarcted area per total area in the 
middle section is compared. n = 7, each 
group. Scale bar: 500 μm. *P < 0.05 
versus WT, Mann-Whitney U test. Error 
bars represent mean ± SD.
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of Angpt2 in the recruitment of inflammatory cells by increasing 
adhesion molecules in the ECs of other tissues and organs (14, 25, 
35), we decided to investigate the effect of EC-derived Angpt2 on 
vascular inflammation after MI using Angpt2iΔEC mice. Adhesion 
molecules were abundantly expressed in ECs 3 days after MI, 
including E-selectin, L-selectin, VCAM-1, and ICAM-1 (Figure 
5, A and B, and Supplemental Figure 7, A and B). Interestingly, 
Angpt2iΔEC mice showed lower (40%–63%) expression of these 
adhesion molecules; consequently, Gr-1+ neutrophil infiltration was 
52% lower than in WT mice (Figure 5, A and B). Notably, increased 
expression of the NF-κB p65 protein on ECs, a major transcription-
al factor for inflammation that is suppressed by Tie2 signaling in 
quiescent ECs (30), was remarkably attenuated in Angpt2iΔEC mice 
compared with WT mice (Figure 5, A and B), endorsing the exacer-
bating role of Angpt2 on vascular inflammation through the upreg-
ulation of NF-κB activity after MI. Accordingly, expression levels 
of E-selectin in ECs at the border zone were further aggravated by 
conditional deletion of Angpt1 (Angpt1iΔ/Δ) or Tie2 (Tie2iΔEC) (Figure 
5, C and D), implying that endothelial Tie2 acts as a gatekeeper that 
prevents vascular inflammation.
Heparan sulfate (HS) is a major com-
ponent of the endothelial glycocalyx (eGC) 
and cardiac ECM (cECM). HS is degraded 
by heparanase, which is upregulated and 
activated by NF-κB activation during inflam-
mation (40, 41), and suppressed by Tie2 acti-
vation (23). Therefore, we asked whether EC- 
derived Angpt2 and subsequent upregulation 
of NF-κB p65 expression and perturbation of 
Tie2 activity play roles in eGC and cECM deg-
radation by enhancing heparanase activity in 
ECs after MI. Indeed, heparanase expression 
was markedly increased in ECs at the bor-
der zone and in the surrounding infiltrated 
CD45+ leukocytes 3 days after MI, while no 
heparanase was detected in the hearts of 
sham-operated control mice (Figure 6, A and 
B). Immunoblot analyses also demonstrated 
marked upregulation of both inactive and 
active heparanase at the infarct border after MI (Figure 6, C and 
D). Using ImageJ software (NIH), we defined each HS of eGC or 
cECM, termed HS-eGC and HS-cECM, respectively (Supplemen-
tal Figure 8, A and B). Well-aligned distributions of HS-eGC and 
HS-cECM were detected in hearts of normal and sham-operated 
control mice (Figure 6E and Supplemental Figure 8A). Compared 
with sham-operated control heart, severe losses and disorgani-
zations of total HS, HS-eGC, and HS-cECM were detected in 
the ischemic regions of hearts 3 days after MI (Figure 6, E and F, 
Supplemental Figure 8B). However, compared with WT MI mice, 
Angpt2iΔEC MI mice showed reduced heparanase levels (~57%) and 
preserved total HS (~52%), HS-eGC (~59%), and HS-cECM (~26%) 
in the ischemic region 3 days after MI (Figure 6, E and F), suggest-
ing a close correlation between the Angpt2-mediated heparanase 
expression and HS degradation on the eGC and ECM. On the oth-
er hand, expression of heparanase in ECs at the border zone and 
infiltrated leukocytes were further exaggerated in Angpt1iΔ/Δ mice 
and Tie2iΔEC mice compared with WT mice (Supplemental Figure 
9, A and B), implying the suppressive role of endothelial Tie2 on 
heparanase expression in ischemic heart. Together, these results 
Figure 5. EC-specific depletion of Angpt2 ame-
liorates expressions of adhesion molecules and 
neutrophil infiltration in ischemic heart. Adult 
WT, Angpt1iΔ/Δ, Angpt2iΔEC, or Tie2iΔEC (T2ΔE) mice 
were subject to MI or sham procedure, hearts were 
harvested at 3 days after MI, and indicated mole-
cules in heart sections at the infarct border were 
detected by immunostaining. (A and B) Images  
and comparisons of E-selectin, VCAM-1, and NF-κB 
p65 on ECs and Gr-1+ neutrophil infiltration in the 
infarct border. n = 5–6, each group. Scale bars: 50 
μm, except for Gr-1+ neutrophil infiltration (500 
μm). (C and D) Images and comparisons of  
E-selectin expression on ECs at the infarct border.  
n = 5–6, each group. Scale bars: 100 μm. *P < 0.025, 
Kruskal-Wallis test followed by Mann-Whitney U 
test for post hoc pairwise comparisons. Error bars 
represent mean ± SD.
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indicate that Angpt2 augments vascular destabilization, vascular 
inflammation, and adverse cardiac remodeling that is mediated 
by antagonizing Tie2 signaling during the acute phase of MI.
Angpt2 plays a facilitating role in macrophage polarization toward 
a proinflammatory type. Macrophages have considerable plastici-
ty to adopt phenotypical and functional alterations, called mac-
rophage polarization, in response to inflammatory stimuli (42). In 
particular, proinflammatory M1-like macrophages promote tissue 
damage and adverse cardiac remodeling after MI (43). In contrast, 
those with antiinflammatory properties, termed M2-like mac-
rophages, mitigate myocardial injury (44). Histological analysis 
of the infarct border in MI mice revealed unexpected but distinct 
Angpt2 expression in CD68+ macrophages 7 days after MI (Figure 
7, A and B). This is in accordance with previous in vitro findings (45) 
that hypoxia-induced HIF-1α promotes Angpt2 expression by mac-
rophages. Notably, approximately 93% of Angpt2+ macrophages 
coexpressed inducible NOS (iNOS), a proinflammatory marker 
(Figure 7A). We therefore questioned whether Angpt2 plays a sub-
stantial role in macrophage polarization. However, the infiltrat-
ed macrophages hardly expressed Tie2 (Figure 7C). On the other 
hand, Angpt2 is known to induce the phosphorylation of ERK- and 
FAK-signaling pathways by binding to integrins αvβ3, αvβ5, and α5β1 
in Tie2-low or Tie2-negative cells (11), and ERK activation induces 
the proinflammatory polarization of macrophages (46). Intriguing-
ly, CD68+ cardiac macrophages highly expressed integrin α5β1 (Fig-
ure 7, C and D), most of which colocalized with Angpt2 (Figure 7E). 
Therefore, we reasoned that Angpt2 might play an important role 
in polarizing macrophages toward a proinflammatory state by bind-
Figure 6. EC-specific depletion of Angpt2 mitigates degradation of eGC and ECM in ischemic heart. Adult WT or Angpt2iΔEC mice were subject to MI or 
sham procedure, hearts were harvested at 3 days after MI, and indicated molecules in heart sections at the infarct border were detected by immunostain-
ing. (A and B) Images and comparisons showing increased heparanase in ECs and infiltrating CD45+ leukocytes. n = 5–6, each group. Scale bars: 50 μm. 
*P < 0.05 versus sham, Mann-Whitney U test. (C and D) Immunoblot and densitometric analyses of heparanase expression and activation at the infarct 
border after MI. n=3, each group. *P < 0.05 versus sham, Mann-Whitney U test. (E and F) Images and comparisons of heparanase expression, HS-eGC den-
sity, and HS-cECM density. n = 5–6, each group. Scale bars: 50 μm. *P < 0.025, Kruskal-Wallis test followed by Mann-Whitney U test for post hoc pairwise 
comparisons. Error bars represent mean ± SD.
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may induce proinflammatory 
macrophage polarization that 
is mediated by the activation of 
the integrin α5β1/ERK-signaling 
pathway in autocrine and para-
crine manners.
To determine whether 
Angpt2 plays a facilitating role 
in proinflammatory macro-
phage polarization through 
the integrin α5β1/ERK–signal-
ing pathway, we used globally 
Angpt2-depleted (Angpt2iΔ/Δ) 
mice that were generated by 
crossing Angpt2fl/fl mice (47) 
with UBC-Cre-ERT2 mice (Fig-
ure 7G). Compared with WT 
mice, in Angpt2iΔ/Δ mice (gene 
deletion efficiency, 85%, Sup-
plemental Figure 5 and Sup-
plemental Table 1), phosphor-
ylated ERK (pERK) expression 
in CD68+ macrophages was 
reduced by 66% at 7 days after 
MI (Figure 7, H and I). We also 
determined whether inhibi-
tion of integrin α5β1 mitigates 
pERK expression in CD68+ 
cardiac macrophages. Treat-
ment of ATN-161, a specific 
peptide-based inhibitor against 
integrin α5β1, after MI (Figure 7J) 
also markedly reduced pERK 
expression levels in CD68+ 
macrophages, by 78% (Fig-
ure 7, K and L), supporting our 
hypothesis that Angpt2/integ-
rin α5β1 signaling contributes to 
ERK phosphorylation of CD68+ 
macrophages after MI. Further, 
we evaluated the expression 
profile of pro- and antiinflam-
matory markers in CD68+ mac-
rophages of WT and Angpt2iΔ/Δ 
mice at 7 days after MI (Figure 
8A). Expression of iNOS and 
MHC II in CD68+ macrophages 
was reduced in Angpt2iΔ/Δ mice 
by approximately 57% and 
approximately 56%, respec-
tively, while the expression of 
CD206 and arginase-1 (Arg-1), 
which are antiinflammatory markers, was not significantly differ-
ent, resulting in a decreased iNOS/CD206 ratio (Figure 8, B and 
C). Treatment of integrin α5β1–inhibitory peptide also remarkably 
mitigated iNOS expression in CD68+ macrophages, by 69% (Fig-
ure 8, D–F). Taken together, these findings suggest that Angpt2/
ing to the integrin α5β1 receptor and activating ERK. Indeed, ERK 
phosphorylation, as determined by phosphospecific antibody rec-
ognition of ERK1/2 (Thr202/Tyr204), was observed in most of the 
Angpt2+ macrophages (~95%) (Figure 7F). Therefore, we supposed 
that the upregulated Angpt2 expression in macrophages and ECs 
Figure 7. Angpt2/integrin α5β1 signaling is positively associated with pERK expression in macrophages in isch-
emic heart. Adult WT or Angpt2iΔ/Δ (A2ΔU) mice were subject to MI or sham procedure, hearts were harvested at 7 
days after MI, and indicated molecules in heart sections at the border zone were detected by immunostaining. (A 
and B) Images and comparisons of Angpt2 expression in CD68+ macrophages. Box region is magnified below. Note 
colocalization of Angpt2 and iNOS (white arrows). n = 5–6, each group. Scale bars: 50 μm. HPF, high-power field.  
*P < 0.05 by Mann-Whitney U test. (C and D) Images and comparisons of expression of Tie2 and integrin α5β1 (i-α5β1) 
in CD68+ macrophages. Scale bars: 20 μm. n = 4–5, each group. *P < 0.05 by Mann-Whitney U test. (E) Images 
showing colocalization of integrin α5β1 and Angpt2 in CD68
+ macrophages (white arrowheads). Scale bars: 20 μm. (F) 
Images showing colocalization of pERK (at Thr202/Tyr 204) and Angpt2 in CD68+ macrophages (white arrowheads). 
Scale bars: 20 μm. (A, E, and F) Each area marked by a yellow box is magnified in the left bottom corner. (G) Dia-
gram depicting generation of Angpt2iΔ/Δ mice and their experiment schedule. (H and I) Images and comparisons of 
pERK in CD68+ macrophages. n = 5–6, each group. Scale bars: 100 μm. *P < 0.025, Kruskal-Wallis test followed by 
Mann-Whitney U test for post hoc pairwise comparisons. (J) Diagram depicting the experiment schedule for integrin 
α5β1 inhibitor treatment (ATN-161, 30 mg/kg, intraperitoneal injection) after MI. (K and L) Images and comparisons 
of pERK in CD68+ macrophages. n = 4–5, each group. Scale bars: 100 μm. *P < 0.05, Mann-Whitney U test. Error 
bars represent mean ± SD.
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depletion exerted negligible effects (Supplemental Figure 10, 
D–G), implying the dominant role of macrophage-derived Angpt2 
in determination of macrophage polarity after MI.
Angpt2 continuously drives adverse vascular remodeling in the 
infarct border zone. We further investigated whether Angpt2 has a 
sustained effect on vascular remodeling by analyzing the infarct 
border zone 2 and 3 weeks after MI. Of special note, Angpt2 expres-
sion was still high in the ECs at these time points (Figure 9, A and B). 
Notably, severely disorganized or disintegrated vessels at the border 
integrin α5β1 signaling plays an important role in establishing an 
inflammatory microenvironment after myocardial ischemia by 
promoting proinflammatory macrophage polarization.
To elucidate whether macrophage- or endothelial-driven 
Angpt2 plays a major role in macrophage polarization, we generat-
ed Angpt2ΔMΦ mice by crossing Angpt2fl/fl mice (27) with LysM-Cre 
mice (48) (Supplemental Figure 10, A–C). Macrophage-specific 
depletion of Angpt2 markedly diminished ERK phosphorylation 
and proinflammatory macrophage polarization, while EC-specific 
Figure 8. Angpt2 plays a substantial role in proinflammatory macrophage polarization in ischemic heart. Adult WT or Angpt2iΔ/Δ mice were subject to MI 
or sham procedure, hearts were harvested at 7 days after MI, and indicated molecules in heart sections at the infarct border were detected by immu-
nostaining. (A) Diagram depicting generation of Angpt2iΔ/Δ mice and their experiment schedule. (B) Images of expression of iNOS, CD206, MHC II, and 
Arg-1 in CD68+ macrophages. Scale bars: 50 μm. (C) Comparisons of indicated parameters. n = 5–6, each group. *P < 0.025. Kruskal-Wallis test followed 
by Mann-Whitney U test for post hoc pairwise comparisons. Significance was adjusted for multiple comparisons using Bonferroni’s method. Error bars 
represent mean ± SD. (D) Diagram depicting the experiment schedule for integrin α5β1 inhibitor treatment (ATN-161, 30 mg/kg, intraperitoneal injection) 
after MI. (E and F) Images and comparisons of iNOS expression in CD68+ macrophages. n = 4–5, each group. Scale bars: 100 μm. *P < 0.05, Mann-Whitney 
U test. Error bars represent mean ± SD.
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To gain insights into the mechanisms involved in Angpt2- 
induced vascular remodeling, we examined the expression of puta-
tive receptors and signaling molecules downstream of Angpt2. Of 
note, strong expression of integrin α5β1, which is not expressed in 
ECs of sham-operated control hearts, was observed in ECs at border 
zones of chronic ischemic hearts of WT and Angpt2iΔ/Δ mice (Figure 
9, F and G). FAK phosphorylation, as detected by phosphospecif-
ic antibody recognition of the Tyr397 autophosphorylation site of 
FAK (pFAK-Tyr 397), was observed on the vessels of WT mice that 
were undergoing remodeling, but the level was substantially lower 
in Angpt2iΔ/Δ mice (Figure 9, F and G). The integrin dependence of 
Angpt2-induced FAK phosphorylation was further confirmed by 
knockdown of integrin α5 or integrin β1 from HUVECs, which led 
to diminished Angpt2-induced FAK phosphorylation (Figure 9H). 
Given that FAK significantly contributes to formation of abnormal 
zone exhibited higher Angpt2 levels and distinct FOXO1 nuclear 
localization (Figure 9, A–C), indicating that disrupted ECs retained 
activated FOXO1 transcriptional activity and thereby increased 
Angpt2 expression in a positive feedback manner. Compared with 
sham-operated control hearts, marked impairments of NG2+ peri-
cyte coverage, collagen type IV+ (Col IV) basement membrane, and 
ZO-1+ tight junction on the ECs were detected at the infarct border 
zone 2 weeks after MI. To investigate whether Angpt2 from any 
source, i.e., from either ECs or from polarized macrophages, plays a 
role in chronic vascular remodeling, we used Angpt2iΔ/Δ mice rather 
than Angpt2iΔEC mice. Compared with those from WT mice, the ECs 
of Angpt2iΔ/Δ mice showed better NG2+ pericyte coverage (~37%), 
more Col IV+ basement membrane (~40%), more ZO-1+ tight junc-
tions (~47%), and greater FITC-lectin+ perfusion (~62%) (Figure 9, 
D and E, and Supplemental Figure 11, A and B).
Figure 9. Angpt2 contributes to 
adverse vascular remodeling, 
thereby inhibiting effective 
microvascular perfusion in chron-
ically ischemic heart. Adult WT 
or Angpt2iΔ/Δ mice were subject to 
MI or sham procedure, hearts were 
harvested at 2 weeks after MI, 
and indicated molecules in heart 
sections at the infarct border were 
detected by immunostaining. (A 
and B) Images and comparisons of 
Angpt2 in ECs of remodeling ves-
sels at the border zone. Each box 
region is magnified in right corner. 
Note high Angpt2 in the disinte-
grated ECs. n = 5, each group. Scale 
bars: 50 μm. (C) Images showing 
nuclear localization of FOXO1 in 
Angpt2+ ECs of the remodeling 
vessels. Boxed region is magnified 
in left corner. Scale bar: 50 μm. (D 
and E) Images and comparisons 
of NG2+ pericyte coverage and 
FITC-lectin perfusion in ECs. n = 
5–6, each group. Scale bars: 50 μm. 
(F and G) Images and comparisons 
of i-α5β1 and FAK phosphorylation 
at Tyr397 (pFAK-Tyr 397) in ECs. 
Each boxed region is magnified in 
left corner. n = 5–6, each group. 
Scale bars: 50 μm. (H) Immu-
noblot images showing reduced 
Angpt2-induced FAK phosphory-
lation in HUVECs transfected with 
siRNAs for integrin α5 (siITGA5), 
integrin β1 (siITGB1), or scrambled 
control (siCont). (B, E, and G) Com-
parisons of indicated parameters. 
*P < 0.025, Kruskal-Wallis test 
followed by Mann-Whitney U test 
for post hoc pairwise comparisons. 
Significance was adjusted for mul-
tiple comparisons using Bonfer-
roni’s method. Error bars represent 
mean ± SD.
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observed in our study. Furthermore, the GSEA 
data revealed a decreased association with the 
GO term proteinaceous ECM in Angpt2iΔ/Δ mice 
compared with WT mice (Figure 10A), which is 
a resultant phenotype of EndoMT. These GSEA 
findings support the notion that Angpt2 plays a 
dominant role in exacerbating adverse vascular 
remodeling after MI.
Genetic or pharmacological inhibition of 
Angpt2 ameliorates postischemic cardiovascular 
remodeling. Finally, we asked whether genet-
ic depletion or pharmacological inhibition of 
Angpt2 could mitigate infarct progression and 
consequent heart failure. Indeed, pericyte 
detachment, RBC leakage, heparanase expres-
sion, leukocyte infiltration, proinflammatory 
macrophage polarization, and vascular adverse 
remodeling were all effectively mitigated by 
anti-Angpt2 antibody treatment (23) (Figure 11, 
A and B). Furthermore, antibody-mediated neu-
tralization of Angpt2 suppressed the excessive 
activation of integrin β1 in the infarct border ECs, reinforcing our 
suggestion that Angpt2 activates integrin α5β1 after MI (Supple-
mental Figure 12). Consequently, global depletion of Angpt2 or 
treatment with an anti-Angpt2 blocking antibody 6 hours after MI 
(Figure 12A) attenuated infarct progression by approximately 57% 
and approximately 43% at 3 weeks after MI, respectively (Figure 
12, B and C). Cardiac fibrosis, as measured by fibronectin depo-
sition 3 weeks after MI, was also consistently lower in Angpt2iΔ/Δ 
mice (~60%) and in anti-Angpt2 antibody–treated mice (~42%) 
(Figure 12, D and E).
To determine whether Angpt2 depletion/inhibition had a pro-
tective effect on cardiac function, we measured the left ventricu-
lar systolic function by echocardiography 3 weeks after MI (Figure 
12F). Intriguingly, genetic depletion of Angpt2 or anti-Angpt2 anti-
body treatment effectively mitigated the decrease in ejection frac-
tion (~49% and ~33%), stroke volume (~48% and ~37%), and car-
diac output (~49% and ~36%), respectively (Figure 12, F and G).
We also investigated whether Angpt2 plays a crucial role in car-
diac ischemia/reperfusion (I/R) using a mouse model. Similarly to 
the spatiotemporal expression pattern in MI, distinct FOXO1 nucle-
ar localization and Angpt2 expression by ECs was observed in the 
vasculature around the tumor by increasing EC migration and 
permeability (49), these data imply that Angpt2 promotes adverse 
vascular remodeling through integrin α5β1 binding and FAK phos-
phorylation in the ischemic heart.
To further evaluate the impact of Angpt2 on chronic vas-
cular remodeling, we performed gene expression profiling on 
ECs of the border zone that were freshly isolated from infarcted 
hearts using 3′ mRNA sequencing (50, 51). Intriguingly, gene set 
expression analysis (GSEA) showed the downregulation of genes 
related to the epithelial mesenchymal transition (EMT) in the 
ECs of Angpt2iΔ/Δ mice relative to those of WT mice (Figure 10, A 
and B). mRNA expression of the genes (Col12a1, Wnt5a, Lamc2, 
Fstl3, Pcolce) involved in endothelial-to-mesenchymal transition 
(EndoMT) were also significantly decreased in the heart ECs of 
Angpt2iΔ/Δ mice compared with those of WT mice (Figure 10C and 
Supplemental Table 1). The EndoMT is a specialized form of EMT 
that is characterized by the loss of endothelial identity and the 
acquisition of mesenchymal and stem-like characteristics by ECs 
(52). Notably, EndoMT contributes to the disintegration of the 
vascular barrier and to abnormal vascular remodeling of the brain 
microvasculature (53), which are similar to the vascular changes 
Figure 10. Genetic depletion of Angpt2 mitigates 
expression of EndoMT-related genes. Adult WT or 
Angpt2iΔ/Δ (A2ΔU) mice were subject to MI, and the 
infarct border zone ECs were freshly isolated at 2 
weeks after MI. (A) GSEA of isolated ECs at the border 
zone showing downregulation of the genes of EMT sig-
nature and GO terms proteinaceous ECM in Angpt2iΔ/Δ 
mice compared with WT mice. ES, enrichment score. 
NES, normalized enrichment score. n = 3–4, each 
group. (B) Heatmap of EMT signature genes of ECs 
sorted from WT and Angpt2iΔ/Δ mice. (C) The relative 
expression level of each EndoMT-related gene was 
confirmed by quantitative PCR (n = 3, each group).  
*P < 0.05 versus WT, Mann-Whitney U test. Error bars 
represent mean ± SD.
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Angpt2 in postischemic cardiovascular remodeling. We recently 
reported that the FOXO1/Angpt2 axis suppresses the endotheli-
al PI3K/Akt-signaling pathway, the main downstream pathway 
for Tie2 that plays a vital role in maintaining vascular integrity, 
inducing vascular destabilization in a positive feedback man-
ner (25), and that it is central to the pathogenesis of sepsis (23), 
diabetic retinopathy (25), and tumor vessel destabilization (38). 
This study provides additional insights into the serious detri-
mental effects of the FOXO1/Angpt2 axis in exacerbating cardi-
ac hypoxia and infarct progression by impairing effective perfu-
sion of the ischemic border.
Our study also highlights the substantial role of Angpt2- 
induced vascular inflammation in cardiovascular remodeling. In 
quiescent ECs, Angpt1/Tie2 signaling recruits an intracellular 
protein, A20-binding inhibitor of NF-κB activation 2 (ABIN2), 
which strongly inhibits the NF-κB pathway (25, 36), whereas 
Angpt2 activates the NF-κB pathway to further aggravate vascu-
lar inflammation and augment adhesion molecule expression (17, 
55). Accordingly, this study demonstrated that Angpt2 substan-
tially contributes to the upregulation of NF-κB p65 expression 
in ECs of the border zone and increases the expression of hepa-
ranase and adhesion molecules, leading to robust infiltration of 
inflammatory cells and disorganization/degradation of eGC and 
cECM. Furthermore, our data show the preferential expression 
of Angpt2 by proinflammatory macrophages and the colocal-
ization of Angpt2 with a putative receptor, integrin α5β1, and its 
downstream effector, pERK. Previous studies have highlighted 
the crucial role of the ERK pathway in determining the character-
istics of proinflammatory macrophages (46, 56). Here, we show 
that genetic deletion or pharmacological inhibition of Angpt2/
reperfused area starting 2 days after the I/R injury (Supplemental 
Figure 13, A–D). Moreover, Angpt2 substantially contributed to vas-
cular barrier disruption, vascular inflammation, proinflammatory 
macrophage polarization, and adverse vascular remodeling after 
I/R injury, and this was markedly alleviated by anti-Angpt2 antibody 
treatment (Supplemental Figure 13, E and F). Consequently, anti-
Angpt2 antibody treatment greatly mitigated left ventricular wall 
thinning and infarct progression after I/R injury (Figure 12, H–J).
Discussion
This study demonstrated that Angpt2 plays crucial roles in EC 
destabilization and remodeling in the infarct border zone after MI 
and provided insights into the contribution of Angpt2 to the proin-
flammatory milieu (Figure 13). Intriguingly, EC-specific deletion 
of Angpt2 preserved endothelial barrier integrity and quiescence 
after MI; this led to improved cardiac oxygenation and marked 
reduction of the infarct area in the acute phase of MI. Moreover, 
global deletion of Angpt2 mitigated proinflammatory macrophage 
polarization and adverse vascular remodeling in the chronic 
remodeling phase. It was especially noteworthy that genetic or 
antibody-mediated pharmacological inhibition of Angpt2 mark-
edly ameliorated cardiac hypoxia and inflammation and the con-
sequent progression of heart failure.
This study demonstrates the distinct spatiotemporal expres-
sion profile of Angpt2 after MI and I/R, which, to date, has 
been obscure due to a lack of reliable antibodies (54). Using our 
recently developed anti-Angpt2 antibody (23), which is highly 
sensitive and specific to Angpt2, we demonstrate distinct expres-
sions of Angpt2 on the ECs and proinflammatory macrophages 
after ischemia. This prompted us to further investigate the role of 
Figure 11. Therapeutic inhibition 
of Angpt2 prevents vascular 
disintegration, permeability, 
inflammation, adverse remod-
eling, and proinflammatory 
macrophage polarization after MI. 
Fc or α-Angpt2 (α-A2) (20 mg/kg, 
intraperitoneally) was adminis-
tered to WT mice at 6 hours after 
MI or sham procedure, followed 
by repeated injection of the same 
dose at 1 week intervals. (A and B) 
Images and comparisons of NG2+ 
pericyte coverage, TER119+ RBC 
leakage, heparanase expression, 
CD45+ leukocytes infiltration at 
3 days after, iNOS+ macrophage 
count and proportion at 7 days 
after, and NG2+ pericyte coverage 
at 14 days after MI. n = 5–6, each 
group. Scale bars: 50 μm. *P < 
0.025, Kruskal-Wallis test followed 
by Mann-Whitney U test for post 
hoc pairwise comparisons. Error 
bars represent mean ± SD.
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Previous reports suggest the critical roles of the Angpt-Tie2 
system in vascular remodeling (34, 55) and tumor angiogenesis 
(38), but the precise role of Angpt2 in vascular remodeling in isch-
emic organs is not fully understood. This study demonstrates that 
Angpt2 promotes adverse vascular remodeling in ischemic hearts 
via the Angpt2/integrin α5β1/FAK–signaling pathway. We note that 
the infarct border vessels with disintegrated morphology highly 
expressed pFAK-Tyr 397 as well as Angpt2. FAK is a multifacet-
integrin α5β1 signaling decreases ERK phosphorylation and proin-
flammatory macrophage polarization, in accordance with the 
findings of an in vitro study (57), which strongly suggests that 
Angpt2 elicits ERK phosphorylation and proinflammatory macro-
phage polarization after myocardial ischemia. Collectively, these 
results suggest that Angpt2 plays an integral role in establishing 
an inflammatory cardiac milieu by augmenting neutrophil infil-
tration and proinflammatory macrophage polarization.
Figure 12. Genetic deletion or blocking antibody of Angpt2 ameliorates infarct size and adverse cardiac remodeling after myocardial ischemia. Adult 
WT or Angpt2iΔ/Δ mice were subject to MI, I/R, or sham procedure, and hearts were analyzed at 3 weeks after the procedure. (A) Diagram depicting prepa-
ration of animals and experimental schedules. Fc or α-Angpt2 (20 mg/kg, intraperitoneally) was administered to WT or Angpt2iΔ/Δ mice at 6 hours after 
MI, followed by repeated injections of the same dose at 1-week intervals. (B and C) Images and comparisons of infarction area. n = 5–6, each group. Scale 
bars: 1 mm. (D and E) Images and comparisons of cardiac fibrosis represented by fibronectin+ area. n = 6, each group. Scale bars: 1 mm. (F and G) Images 
and comparisons of cardiac systolic function evaluated by echocardiography. n = 6, each group. (C, E, and G) Comparisons of indicated parameters. *P < 
0.025, Kruskal-Wallis test followed by Mann-Whitney U test for post hoc pairwise comparisons. Significance was adjusted for multiple comparisons using 
Bonferroni’s method. (H–J) Fc or α-Angpt2 (20 mg/kg, intraperitoneally) was administered to WT mice at 6 hours after I/R, followed by repeated injections 
of the same dose at 1 week intervals. Images of cardiac fibrosis determined by Masson trichrome stain and comparisons of indicated parameters. n = 6, 
each group. Scale bars: 1 mm. *P < 0.05 versus WT, Mann-Whitney U test. Error bars represent mean ± SD.
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a putative mechanism for Angpt2-induced vascular remodeling, 
and this is supported by the well-recognized augmenting role of 
FAK signaling in EMT/EndoMT progression (49).
Myocardial ischemia and the subsequent reperfusion induced 
by percutaneous coronary intervention or cardiac surgery after MI 
elicit a robust inflammatory response and cause additional damage 
to the heart, despite their myocardial salvaging effects (62, 63). In 
this regard, mitigating inflammation and reperfusion injury after 
MI and subsequently reducing infarct size are the primary goals for 
preventing the initiation and progression of ischemic heart failure 
(39, 62). Importantly, the expression and the deleterious effects 
of Angpt2, which augmented cardiac hypoxia and inflammation, 
were recapitulated in an I/R model, suggesting the integral role of 
Angpt2 in the pathogenesis of postischemic cardiovascular remod-
eling. While a previous report has shown that 3-hydroxy-3-methyl- 
glutaryl-CoA reductase inhibitors may suppress the FOXO1/
Angpt2 axis through in vitro drug screening (64), the exact mech-
anism remains unclear and the effects are yet to be demonstrated 
in vivo. Meanwhile, in our study, the antibody-mediated inhibition 
of Angpt2 considerably abrogated Angpt2-induced vascular disin-
ed regulator of intracellular signaling that is involved in processes 
such as cell motility, survival, and proliferation in various tumor 
cells and in the surrounding microenvironment components, 
including ECs (49). Indeed, FAK plays a critical role in vascular 
remodeling, and orthotropic glioma implantation in FakiΔEC mice 
results in tumor vessel normalization (58), similar to the normal-
ized morphology of the vessels in the infarct border area in Ang-
pt2iΔ/Δ mice. Together with normalization of vascular morphology, 
Angpt2 deletion led to marked reduction of pFAK-Tyr 397 expres-
sion in infarct border area vessels at the chronic remodeling phase, 
reinforcing the idea that Angpt2/integrin α5β1/FAK signaling is the 
main driver of vascular remodeling in ischemic conditions.
The EndoMT is a fundamental step in the development of car-
diac valves (59), and interestingly, the emergence of cardiac peri-
cytes and vascular smooth muscles cells derived from ECs through 
EndoMT has also been recognized (60). Moreover, a recent study 
(61) showed that Angpt2 induces cerebral cavernous malforma-
tion through the EndoMT, and this was effectively normalized by 
an anti-Angpt2 blocking antibody. In accordance with these stud-
ies, our GSEA findings strongly suggest that the EndoMT serves as 
Figure 13. Schematic diagram depicting 
the roles of Angpt2 in exacerbating cardiac 
hypoxia and inflammation after myocar-
dial ischemia. Myocardial ischemia induces 
disintegration of endothelial barrier, abnor-
mal vascular remodeling, robust inflamma-
tory responses, and ECM disorganization, 
and these pathological changes can be 
effectively mitigated by Angpt2 blockade. 
Mechanistically, in ECs, the increase in 
Angpt2 expression is directly regulated by 
FOXO1, which antagonizes Tie2 signaling 
and consequently attenuates PI3K/Akt 
signaling and enhances NF-κB p65 and 
FOXO1 expression. Thus, increased FOXO1 
transcriptional activity forms a positive 
feedback loop with Angpt2 and exerts a sus-
tained effect on ECs, leading to destabiliza-
tion and remodeling. Pericyte detachment 
and EC destabilization presumably due to 
attenuated PI3K/Akt signaling exacerbate 
vascular leakage. Enhanced activity of 
NF-κB p65 augments endothelial expression 
of heparanase and adhesion molecules, 
further promoting inflammatory cell recruit-
ment and ECM disorganization. In addition, 
Angpt2/integrin α5β1 signaling promotes 
abnormal vascular remodeling through 
FAK phosphorylation, resulting in chronic 
hypoxia. In macrophages, the Angpt2/
integrin α5β1/ERK–signaling pathway plays 
an important role in proinflammatory 
macrophage polarization in autocrine and 
paracrine manners. These exacerbating roles 
of Angpt2 in cardiac hypoxia and inflamma-
tion after myocardial ischemia eventually 
trigger deterioration of cardiac structure and 
function, leading to heart failure.
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opened in the third intercostal space, and permanent suture by 8-0 
prolene was made for the MI procedure. Complete occlusion of the left 
anterior descending (LAD) artery was confirmed by the presence of 
myocardial blanching. For the I/R injury model, a 7-0 prolene suture 
was made with a section of PE-10 tubing placed over the LAD artery, 
1 mm below the tip of the left atrium. After occlusion for 30 minutes, 
the ligature was released by removing PE-10 tubing for reperfusion of 
LAD. After permanent or temporary ligation of LAD, the chest wall 
was closed with 6-0 silk suture. Sham-operated mice underwent the 
same procedure without coronary artery ligation. Animals were not 
randomized; however, procedures were performed by researchers 
blinded to the genotype and drug- or antibody-treatment group.
For more information, see Supplemental Methods.
Statistics. Values are presented as mean ± SD. Statistical differenc-
es between the means were compared by the 2-sided Mann-Whitney 
U test for 2 groups and by the Kruskal-Wallis test followed by Bon-
ferroni’s correction for multiple groups. Statistical analysis was per-
formed with PASW Statistics 18 (SPSS). Statistical significance was set 
to a P value of less than 0.05.
Study approval. Animal care and experimental procedures were 
approved by the Animal Care Committee of KAIST (no. KA2013-40). 
Mice were housed in accordance with the Institutional Animal Care 
and Use Committee regulations at KAIST.
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tegration, vascular inflammation, proinflammatory macrophage 
polarization and adverse vascular remodeling, even when the 
antibody was injected 6 hours after MI or I/R to mimic a clinically 
relevant situation. Further, in line with evidence that hypoxia and 
inflammation play an important part in triggering and promoting 
tissue fibrosis (65), our findings highlight that pharmacological 
inhibition of Angpt2 markedly ameliorates cardiac fibrosis and 
decline in cardiac function after myocardial ischemia. These find-
ings provide mechanistic insights that could enormously expand 
the therapeutic repertoire for ischemic heart disease.
Together, the results of this study elucidate the integral roles of 
Angpt2 in the pathogenesis of postischemic cardiovascular remod-
eling and designate Angpt2 as a promising therapeutic target, in 
which inhibition of Angpt2 markedly ameliorates cardiac hypoxia 
and inflammation and subsequently prevents ischemic heart failure.
Methods
Mice. Specific pathogen–free (SPF) C57BL/6J mice, Tie2-GFP mice, 
and UBC-Cre-ERT2 mice were purchased from the Jackson Laborato-
ry. Angpt2-EGFP mice (Tg [Angpt2-EGFP] DJ90Gsat/Mmucd) were 
purchased from the Mutant Mouse Regional Resource Center. Angpt1-
GFP mice (29) were provided by Sean Morrison (University of Texas 
Southwestern Medical Center, Dallas, Texas, USA). Foxo1fl/fl mice were 
provided by Ronald A. DePinho (University of Texas MD Anderson 
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